Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FX3P
|
|||
| Former ID |
DCL001045
|
|||
| Drug Name |
ISIS 104838
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9] | Discontinued in Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Discontinued in Phase 2 | [1] | ||
| Therapeutic Class |
Antisense
|
|||
| Company |
Isis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TNFA messenger RNA (TNF mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013426) | |||
| REF 2 | Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.